Telix Pharmaceuticals announces Health Canada approval of Illuccix

Telix Pharmaceuticals announces that Health Canada has approved the use of Illuccix in selecting patients for PSMA1-targeted radionuclide therapy. The label expansion means that Illuccix is now approved in Canada to select patients with progressive metastatic castration-resistant prostate cancer for treatment with the only approved PSMA-targeted radionuclide therapy. To qualify for PSMA-targeted therapy, patients must be imaged with an approved gallium-based PSMA-PET3 agent4, such as Illuccix. The latest approval expands the clinical utility for Illuccix, which has been approved in Canada since October 2022 for staging and re-staging intermediate and high-risk prostate cancer, and localizing tumor tissue in recurrent prostate cancer5. Illuccix is available across Canada through Telix’s partner Isologic Innovative Radiopharmaceuticals, whose distribution network services 265 hospitals and clinics nationwide.